Detalhe da pesquisa
1.
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
Cell
; 173(7): 1770-1782.e14, 2018 06 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29906450
2.
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.
Nature
; 623(7989): 1053-1061, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37844613
3.
Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer.
Prostate
; 84(8): 747-755, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38544345
4.
Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate Cancer.
Lab Invest
; 103(11): 100245, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37652207
5.
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Lancet
; 399(10323): 447-460, 2022 01 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34953525
6.
Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function.
Mol Cell
; 58(6): 925-34, 2015 Jun 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-26091341
7.
Bench to Bedside Development of [18F]Fluoromethyl-(1,2-2H4)choline ([18F]D4-FCH).
Molecules
; 28(24)2023 Dec 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38138508
8.
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study.
Int J Cancer
; 150(6): 993-1006, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34724226
9.
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Int J Cancer
; 151(3): 422-434, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35411939
10.
Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies.
Cancer
; 128(17): 3185-3195, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35737639
11.
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.
Lancet
; 398(10295): 131-142, 2021 07 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34246347
12.
Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses.
Oncologist
; 27(10): e783-e795, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36124924
13.
Multiparametric bone MRI can improve CT-guided bone biopsy target selection in cancer patients and increase diagnostic yield and feasibility of next-generation tumour sequencing.
Eur Radiol
; 32(7): 4647-4656, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35092476
14.
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
Lancet Oncol
; 22(9): 1250-1264, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34388386
15.
A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours.
Br J Cancer
; 124(2): 391-398, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33020594
16.
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.
Lancet Oncol
; 21(11): 1478-1488, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33128873
17.
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol
; 21(1): 162-174, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31806540
18.
First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
Br J Cancer
; 123(12): 1730-1736, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32989226
19.
Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival.
Br J Cancer
; 122(6): 801-811, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31937922
20.
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
N Engl J Med
; 377(4): 338-351, 2017 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-28578639